Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024 Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Feb. 6, 2025 /PRNewswire/ -- Today, the American Diabetes Association ® (ADA ... The resources are part of a nationwide collaboration between Lilly and the ADA to destigmatize obesity and ...

INDIANAPOLIS — Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 ...

(AP Photo/Darron Cummings, File) Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better ...

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... LLY’s GLP-1 therapy tirzepatide, branded as Mounjaro and Zepbound for diabetes and weight loss, respectively, powered the company’s Q4 ...